Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Emerald BioVentures is a life sciences incubator founded on February 2, 2021, in New York, NY. The organization is dedicated to addressing significant challenges in the healthcare sector by leveraging advancements in science and medicine. It operates as both an incubator and an investor, focusing on ideation and company formation. Emerald BioVentures provides capital advisory and operational support for clinical and digital health ventures.
Currently, the firm manages a portfolio of 8 companies and has a team with over 25 years of experience in venture capital and commercializing university research. The organization emphasizes a hands-on approach to company formation and growth, ensuring that its portfolio companies receive the necessary guidance to navigate the complexities of the life sciences sector.
Emerald BioVentures invests in companies that address complex medical issues, particularly in the biotech, healthcare, and digital health sectors. Their investment strategy spans various stages, including pre-seed, seed, seed-plus, Series A, Series B, and Series C. The firm targets innovative solutions for 'white space' problems in healthcare, such as neurodegenerative diseases, breast cancer, heart failure, and obesity.
The organization seeks to identify and develop groundbreaking solutions that can significantly impact human health. Emerald BioVentures emphasizes a hands-on approach to company formation, providing extensive operational support and capital advisory to its portfolio companies. This model allows them to actively participate in the growth and development of their investments.
Emerald BioVentures has invested in several notable companies, including:
This diverse portfolio reflects Emerald BioVentures' commitment to advancing innovative healthcare solutions that address critical medical challenges.
Leena Das-Young: Managing Partner with extensive experience in venture capital and company formation.
Tim Opler: Capital Partner, specializing in funding strategies and investment management.
Catherine Smith: Head of Finance, overseeing financial operations and strategy.
Michael Friedman: Executive in Residence, providing strategic guidance and industry insights.
Travis Read: Principal, focusing on portfolio management and operational support.
Ernest Li: Senior Associate, involved in deal sourcing and analysis.
Bryant Jin: Analyst, supporting research and due diligence efforts.
Ellen Porges: Legal Advisor, ensuring compliance and legal support for investments.
Startups interested in pitching to Emerald BioVentures should send their proposals via email to information@emerald.bio. It is essential to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. The firm values clarity and detail in presentations, as this helps them assess the potential of the startup effectively.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process. Startups should ensure that their pitch clearly articulates their innovative approach to addressing complex medical issues.
Emerald BioVentures runs a program under the same name, focusing on incubating life sciences startups. This program provides resources for ideation, company formation, and operational support. Startups participating in the program gain access to capital advisory and fundraising assistance, which are crucial for navigating the early stages of development.
Eligibility for the program typically includes startups in the biotech, healthcare, and digital health sectors that are addressing significant medical challenges. Interested parties can apply by reaching out to Emerald BioVentures through their contact email.
Emerald BioVentures has been actively investing in companies that tackle significant healthcare challenges. Their portfolio includes notable firms like Aikium, Avalo Therapeutics, and Bask Health, indicating a commitment to advancing innovative healthcare solutions. In 2021, the firm peaked in activity, completing a total of 5 tracked investments.
The organization continues to focus on early-stage funding, with an average round size of approximately $600,000. This reflects their strategy of supporting startups in the pre-seed to Series C stages, particularly those addressing complex medical issues.
What are Emerald BioVentures' investment criteria?
Emerald BioVentures focuses on companies that tackle complex medical issues in the biotech, healthcare, and digital health sectors. They invest across various stages, from pre-seed to Series C, and prioritize innovative solutions for significant healthcare challenges.
How can startups apply or pitch to Emerald BioVentures?
Startups can pitch to Emerald BioVentures by sending an email to their general contact at information@emerald.bio. It is advisable to include a detailed deck outlining the business model, market opportunity, and team background.
What makes Emerald BioVentures different from other investors?
Emerald BioVentures operates as both an incubator and an investor, providing extensive operational support and capital advisory to its portfolio companies. Their hands-on approach ensures that startups receive the guidance needed to navigate the complexities of the life sciences sector.
What is the geographic scope of Emerald BioVentures' investments?
The firm primarily invests in North America, focusing on innovative healthcare solutions that address complex medical issues.
What is the average check size for investments made by Emerald BioVentures?
The average round size for investments tracked by Emerald BioVentures is approximately $600,000, indicating a focus on early-stage funding.
What kind of post-investment involvement can portfolio companies expect?
Emerald BioVentures provides extensive operational support, capital advisory, and fundraising assistance to its portfolio companies, leveraging their team's experience to help navigate the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.